AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03691337
Drug: Marcaine 0.25 % Injectable Solution
RxNorm normalized name: Marcaine 0.25 % Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fascia iliaca block with volume 0.22 mL x subject height
Trial: NCT01308814
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal 17β-estradiol (100 ug/day) for 12 months, administered as patches to be worn continuously and replaced once a week. Also, every 2 months, oral micronized progesterone (200 mg/day x 12 days) will be administered.
Trial: NCT01308814
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patches for 12 months, to be worn continuously and replaced once a week. Also, placebo pills will be administered for 12 days every 2 months.
Trial: NCT00933608
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: participants will be asked to take 2 tablets per day to match active drug
Trial: NCT02331589
Drug: Placebo (for KRG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebos with same shape and size were manufactured and at Korea Ginseng Corporation
Trial: NCT02033629
Drug: Ce 1 ng/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCI Remifentanil Ce 1 ng/ml
Trial: NCT02033629
Drug: Ce 2 ng/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCI Remifentanil Ce 2 ng/ml
Trial: NCT02033629
Drug: Ce 3 ng/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCI Remifentanil Ce 3 ng/ml
Trial: NCT01716039
Drug: MTX 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once weekly oral dosing with MTX 12.5 mg (n=40) two weeks prior to the initiation of adalimumab. Randomization will be stratified by disease activity (modified Mayo Score ≤9 or \>9).~Subjects will receive 18 weekly doses of MTX in addition to doses of adalimumab
Trial: NCT04491682
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: At a dosage of 10 mg/day
Trial: NCT04510987
Drug: BAY2433334 single dose in treatment groups 1-4 and 6 as well as on the dialysis free day of treatment 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral
Trial: NCT01882556
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01964157
Drug: LDK378
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDK378 750mg oral administration and continuously (28-day treatment schedule as one treatment cycle)
Trial: NCT02483923
Drug: intravenous PCA only
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: same dose of intravenous patient controlled analgesia (Basal rate 0ml/hr, 0.5mcg/kg of fentanyl, lock-out time 10minutes) is connected to patient only.
Trial: NCT03608241
Drug: Ethinyl estradiol (EE) and levonogestrel (LN)
RxNorm normalized name: estradiol / ethinyl estradiol / levonorgestrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of Oral tablet containing 30 ug EE and 150 ug of LN
Trial: NCT00669825
Drug: ALV003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doses via intragastric tube at dosages of either 100 mg, 300 mg, 900 mg, or 1800 mg
Trial: NCT00669825
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to be administered via intragastric tube
Trial: NCT02482298
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ticagrelor placebo + 45 mg ticagrelor placebo. Drugs taken orally, twice a day (morning and evening at least 12 hours apart) from randomization until the end of treatment
Trial: NCT01685242
Drug: AC-170 0.24%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop in each eye at 2 separate times during a 14 day period
Trial: NCT01685242
Drug: AC-170 0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop in each eye at 2 separate times during a 14 day period
Trial: NCT00812396
Drug: Comparator: low dose testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 200 mg (0.8 mL) testosterone.
Trial: NCT00812396
Drug: Comparator: high dose testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 600 mg (2.4 mL) testosterone.
Trial: NCT00812396
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 0.8 mL placebo saline solution.
Trial: NCT03625778
Drug: MEDI0382
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI0382 will be administered subcutaneously daily according to the MEDI0382 cohorts.
Trial: NCT03625778
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered subcutaneously daily according to the Placebo cohorts.
Trial: NCT00234663
Drug: PTC124
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00811083
Drug: DMSA - dimercaptosuccinic acid
RxNorm normalized name: Dimercaptosuccinic acid
DrugBank: Dimercaptosuccinic acid (DB14089)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose of 10 mg/kg bodyweight 3 doses/day, for 3 days, followed by 11 days off
Trial: NCT00106119
Drug: Liothyronine and Levothyroxine
RxNorm normalized name: LEVOTHYROXINE/LIOTHYRONINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothyroid patients are treated with Liothyronine and Levothyroxine in 2 crossover, randomized phases
Trial: NCT02923830
Drug: Saline-only catheter flush
RxNorm normalized name: T8 Keto Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention group will have their port catheters flushed with saline only.
Trial: NCT01188551
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: fentanyl (2 µg/kg) will be administered intranasally
Trial: NCT01595594
Drug: Systemic Doxycycline and Sham aPDT
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: It will be prescribed a protocol of 100mg/day of Systemic Doxycycline for 14 days
Trial: NCT01595594
Drug: aPDT + Doxycycline Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The aPDT protocol will consist in 5 applications on the experimental time 0, 1, 5, 7 and 14 days.
Trial: NCT00865839
Drug: CLUCOPHAGE® XR 500 mg tablets, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
Trial: NCT01198509
Drug: doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: doxycycline - 100 mg twice per day, for 2 months
Trial: NCT00089349
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00089349
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00589316
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01073852
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill, 1 pill orally twice daily for 9 weeks.
Trial: NCT02803307
Drug: TLC599
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose via intra-articular injection
Trial: NCT00799578
Drug: Cysteamine
RxNorm normalized name: Cysteamine
DrugBank: Cysteamine (DB00847)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug is in enteric-coated capsule form. The dosage will begin at 1g/m-squared body surface area with a maximum dose of 1000mg twice daily. Treatment period is 3-6 months.
Trial: NCT00499746
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral dose, once per day
Trial: NCT00590577
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo i.m. Days 1, 8, 36, 64
Trial: NCT00790478
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Study Pill (5 mg/d) taken once daily, preferably an hour before bedtime, for 12 weeks.
Trial: NCT00265031
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01436656
Drug: LGX818
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01583816
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical application
Trial: NCT03403530
Drug: IgM rich Immunoglobin
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the 'IgM rich immunoglobn' is the normal human immunoglobin containing Human plasma protein 50mg/ml of which immunoglobin is atleast 95% Immunoglobin M (IgM) 6mg Immunoglobin A (IgA) 6mg Immunoglobin G (IgG) 38mg
Trial: NCT01149005
Drug: novorapid / humalog short acting insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-4 units will be injected Subcutaneously (SC), before every main meal.
Trial: NCT00924612
Drug: Oral testosterone undecanoate (containing 300 mg T)
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03357796
Drug: LY03005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg, oral tablets, single dose
Trial: NCT03483779
Drug: placebo pills
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each N-of-1 trial will consist of 6 treatment periods, of which 2 treatment periods are in one group, including 8 weeks of placebo treatment and 8 weeks of ginkgo biloba pills.
Trial: NCT02342691
Drug: Placebo oral rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo preparation will consist of formulated oral rinse without BLXA4-ME and will be identical to the test rinse in color, appearance and taste
Trial: NCT02214888
Drug: BIRB 796 BS, low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02214888
Drug: BIRB 796 BS, high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02214888
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01869036
Drug: caudal anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard caudal anesthesia (Marcaine 2mg/kg)
Trial: NCT01156025
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop 10 times daily at D0 and D1 and 1 drop 5 times daily from D2 to D9 + additionnal treatment (Hyabak® eye drops: 5 times daily from D10 to D30)
Trial: NCT00052390
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00834600
Drug: olmesartan, hydrochlorothiazide, amlodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydrochlorothiazide (HCTZ) 25mg OD, increased to 50 mg OD at 3 weeks. Olmesartan 20 mg OD, to be increased to 40 mg at 3 weeks. Amlodipine 5 mg, may be added at 6 weeks, if BP \>140 mmHg
Trial: NCT00834600
Drug: hydrochlorothiazide (HCTZ) or olmesartan
RxNorm normalized name: hydrochlorothiazide / olmesartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCTZ 25 mg, increasing to 50 mg at 3-4 weeks or Olmesartan 20 mg, increasing to 40 mg at 3-4 weeks. If blood pressure \>140/90 mmHg at 6 weeks, amlodipine 5 mg may be added
Trial: NCT01271907
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 60 mg/kg intravenous (IV) x 2 days
Trial: NCT04249297
Drug: Duphaston® (Dydrogesteron)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intervention. Description of routine practice only. Prescribed Duphaston® according local marketing authorization and international and Russian In-Vitro Fertilization guidelines for luteal phase support as part of an Assisted Reproductive Technology (1 tablet 3 times a day starting at the day of oocyte retrieval).
Trial: NCT04224103
Drug: Inhaled nitric oxide
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stage 1: Patients in whom VA ECMO is being initiated will be invited to participate. Hemodynamic, echocardiographic, and biochemical parameters will be measured immediately prior to iNO administration, and thirty minutes after initiation. After six hours, hemodynamic, echocardiographic, and biochemical parameters will be re-assessed after which iNO will be weaned. All parameters will be re-evaluated 30 minutes after iNO discontinuation.~Stage 2: iNO will be re-initiated 30 minutes prior to the ECMO weaning trial. Hemodynamic, echocardiographic, and biochemical parameter will be recorded immediately prior to iNO administration and then at 30 minutes prior to the ECMO weaning trial. When ECMO weaning is unsuccessful, these parameters will be recorded immediately prior to re-initiation of full flow VA ECMO and 30 minutes thereafter. If successful, data will be collected after the wean and after iNO discontinuation.
Trial: NCT02195700
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets taken twice daily for 12 weeks.
Trial: NCT03871972
Drug: Umbilical Cord Blood Unit
RxNorm normalized name: Bos taurus umbilical cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 infusions of umbilical cord blood (UCB) unit (TNC \> 2.0ⅹ107cells/kg) each 4 months apart and take oral Sirolimus (1 mg/m2/day) for 7 days (from 3 days before UCB infusion until 3 days after UCB infusion)
Trial: NCT02204046
Drug: BIWA 4
RxNorm normalized name: BREATHING CIRCUIT,BIWAZE COUGH,W/MOUTHPIECE,STANDARD
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03353363
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After patients receive their spinal anesthetic and as the Pfannenstiel incision is being closed, an equal volume (20ml, administered via two 10ml syringes) of normal saline will be infiltrated into the wound by the obstetrician team in a standardized fashion.
Trial: NCT01681186
Drug: LY2940680 Capsule(s) (Reference)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally as a capsule(s)
Trial: NCT01681186
Drug: LY2940680 Tablet (Test)
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally as a tablet
Trial: NCT01681186
Drug: Placebo Capsule(s)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally as a capsule(s)
Trial: NCT01895400
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take placebo drug 1T bid po medication for 8 weeks
Trial: NCT02719691
Drug: MLN0128
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive MLN0128 in the dose-escalation and the dose-expansion part of the study.
Trial: NCT00263042
Drug: Placebo (for Rimonabant)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral administration
Trial: NCT00194077
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects in phase 2 will be randomized to active abilify or placebo
Trial: NCT00807586
Drug: Solumedrol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg, given once within 2 hours of the end of the ablation procedure
Trial: NCT00807586
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (1.6 cc)
Trial: NCT02008942
Drug: Enteric-coated aspirin caplets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 325 mg aspirin; once per day for 10 days
Trial: NCT02143856
Drug: 100 mg GLPG1205
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 100 mg GLPG1205 administered as two capsules of 50 mg
Trial: NCT01863069
Drug: (IM) AVONEX®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04379635
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match tislelizumab IV infusion
Trial: NCT02047422
Drug: furosemid/spironolactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: spironolactone (doubling previous spironoalctone dose or add 12.5mg BID if previous non-user)
Trial: NCT02047422
Drug: metolazone/spironolactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no spironolactone (maintaining previous spironolactone dose or not add spironolactone if previous non-user)
Trial: NCT00282087
Drug: gemcitabine, docetaxel, doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycles = 28 days
Trial: NCT00971581
Drug: FDC KETOPROFEN+OMEPRAZOLE
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoprofen + Omeprazole FDC once daily for 4 weeks
Trial: NCT04560816
Drug: ALXN1840
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALXN1840 (120 milligrams) will be administered orally (supratherapeutic dose).
Trial: NCT04560816
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally.
Trial: NCT04624867
Drug: HP-1050 Patch
RxNorm normalized name: HP 502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both articles, HP-1050 and XULANE patch, will be applied simultaneously on the back of each subject.
Trial: NCT02277691
Drug: HCTZ 12.5 mg tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCTZ tablets
Trial: NCT04396548
Drug: Inert tablet containing sugar (placebo)
RxNorm normalized name: inert ingredients Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: : Patients will receive Inert tablet containing sugar (placebo) with small sips of water one hour before arrival in the operation room. All patients will be monitored in with noninvasive blood pressure as well as continuous electrocardiogram (ECG) and pulse oximetry (SpO2). Before placement of spinal anesthesia, all patients will receive an IV bolus of 10mL/kg of Lactated Ringer's . Spinal anesthesia (midline puncture) will be performed in sitting position by a staff anesthetist at L3-L4 or L4-L5 with a 25-gauge Withacre needle injecting 12.5 mg of hyperbaric 0.5% bupivacaine (2.5 mL) with 10μg fentanyl. After injection,the patients will be turned supine
Trial: NCT03707990
Drug: NNC0165-1875
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single dose of subcutaneous (s.c.) NNC0165-1875 injection. The planned doses of NNC0165-1875 are as following: cohort 1 and 7: 0.1 mg, cohort 2 and 8: 0.3 mg, cohort 3 and 9: 0.6 mg, cohort 4 and 10: 1.2 mg, cohort 5 and 11: 2.4 mg and cohort 6: 0.03 mg.
Trial: NCT03707990
Drug: Placebo (NNC0165-1875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single dose of s.c. placebo injection.
Trial: NCT02966288
Drug: Oral NSAID
RxNorm normalized name: Ansaid Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800mg Motrin will be administered. (non-steroidal anti-inflammatory drug (NSAID))
Trial: NCT00140907
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg of oral placebo once daily, with an up-titration to 50 mg placebo once daily in later visits if serum creatinine did not increase more than 25%. Patients take medication in the morning.
Trial: NCT03623789
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Equivalent volume of saline injection before incision, followed by two boluses (1g TXA) three hours later and six hours later.
Trial: NCT01147250
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Sterile aqueous solution; Route of administration: Subcutaneous within 1-hour before breakfast.
Trial: NCT03645096
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule manufactured to mimic pregnenolone capsule.
Trial: NCT00351767
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topically applied
Trial: NCT00631124
Drug: BAY86-4891 (Estradiol / Drospirenone)
RxNorm normalized name: drospirenone / estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monophasic regimen containing estrogen and progestin 1 pre-treatment cycle, 3 treatment cycles
Trial: NCT00631124
Drug: BAY86-4891 (Estradiol / Drospirenone)
RxNorm normalized name: drospirenone / estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triphasic regimen containing estrogen and progestin 1 pre-treatment cycle, 3 treatment cycles
Trial: NCT02563106
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04531475
Drug: X842
RxNorm normalized name: I'm afraid I don't have enough information to determine the full generic name for the drug abbreviation 'X842'. Drug abbreviations can vary and may not be standardized, so without more context about the specific clinical trial data, I cannot provide the full generic name. I apologize that I cannot give you a more definitive answer.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: X842 capsules
Trial: NCT04531475
Drug: X842 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: X842 placebo-matching capsules
Trial: NCT00799448
Drug: insulin NPH
RxNorm normalized name: insulin NPH human isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00123162
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single vaginal dose of placebo and monitored for 4 hours.
Trial: NCT01335256
Drug: BAY1000394
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY1000394 will be administered orally twice a day (bid) in a 4 week on / 2 week off schedule.
Trial: NCT00749333
Drug: AZD8566
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution. Specific dose will be selected by the safety review committee
Trial: NCT00749333
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 10ml oral solution.